Qifan Zhou is a Research Assistant Professor at the Grubbs Institute of SUSTech and holds a Category C Specially Appointed Position under Shenzhen's "Pengcheng Peacock Program". He is also a Senior Associate Engineer in Biotechnology. In 2019, he obtained his Ph.D. in Medicinal Chemistry from SYPU under the supervision of Prof. Guoliang Chen and was awarded the National Scholarship. His research primarily focuses on the discovery and development of small-molecule innovative drugs for the treatment of cancer, viral infections, and inflammation-related diseases. In 2020, he joined Prof. Xumu Zhang’s group at SUSTech, where he played a key role in the preclinical development of the novel oral anti-SARS-CoV-2 drug SHEN26, which has now completed Phase III clinical trial and is in the process of applying for market approval. Zhou has authored or co-authored over 30 SCI papers in journals such as Sci Transl Med, Signal Transduct Tar, Eur J Med Chem, and J Org Chem. He has also applied for more than 20 invention patents, with 9 Chinese patents granted as the primary inventor.

Educational background:

2016.09 – 2019.06   Ph.D., Medicinal Chemistry, SYPU
2012.09 – 2015.06   M.S., Medicinal Chemistry, SYPU
2007.09 – 2011.06   B.S., Environmental Science, SYPU

Work experience:

2023.11 – Present   Research Assistant Professor, Grubbs Institute, SUSTech
2023.01 – 2023.11   Research Director, Medi-X Pingshan, SUSTech
2021.01 – 2022.12   Postdoctoral Fellow, SUSTech

Research Area：

Small molecule drug development based on new mechanisms and new target